2021 News Releases
KING OF PRUSSIA, Pa.
Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period
NEW YORK, NY, USA
Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award
KING OF PRUSSIA, PA
• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.
King of Prussia, Pa
The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study
Osaka, JAPAN and King of Prussia, Pa., USA
Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19
Here's how CSL is working around the world with academia, industry and governments to combat COVID-19
• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.
• TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey.